Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

MDS 2021 | MDS: the role of the multidisciplinary team

Sara Tinsley-Vance • 22 Sep 2021
MDS 2021
Myelodysplastic Syndromes

Sara Tinsley-Vance, PhD, APRN, Moffitt Cancer Center, Florida, USA, highlights the importance the multidisciplinary team plays in the management of myelodysplastic syndromes (MDS). This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.

Disclosures

Sara Tinsley-Vance, PhD, APRN, discloses links to Bristol Myers Squibb, Jazz and Novartis.

More from Sara Tinsley-Vance

A map to support patients and caregivers on the MDS journey
4:22
A map to support patients and caregivers on the MDS journey
Sara Tinsley-Vance • 22 Sep 2021
MDS: QoL considerations
2:36
MDS: QoL considerations
Sara Tinsley-Vance • 24 Sep 2021

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Sara Tinsley-Vance • 6 Dec 2025
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
1:07
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
Sara Tinsley-Vance • 6 Dec 2025
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
5:58
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
Sara Tinsley-Vance • 16 Dec 2025
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
1:30
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
Sara Tinsley-Vance • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals